Want to see HRMY full AI Analyst Report?
HRMY Stock Chart & Stats
$29.99
-$1.07(-3.04%)
At close: 4:00 PM EST
$29.99
-$1.07(-3.04%)
Day’s Range― - ―
52-Week Range$25.52 - $40.87
Previous CloseN/A
Volume87.33K
Average Volume (3M)836.87K
Market Cap
$2.13B
Enterprise Value$1.21K
Total Cash (Recent Filing)$640.92M
Total Debt (Recent Filing)$206.51M
Price to Earnings (P/E)14.0
Beta1.01
Next Earnings
Aug 04, 2026EPS Estimate
0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.52
Shares Outstanding57,892,677
10 Day Avg. Volume874,102
30 Day Avg. Volume836,866
Financial Highlights & Ratios
PEG Ratio1.74
Price to Book (P/B)2.47
Price to Sales (P/S)2.48
P/FCF Ratio6.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$42.00Price Target Upside40.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)3.46
Revenue Forecast (FY)$1.02B
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet & LiquidityA large cash position with low net leverage provides multi-year financial flexibility to fund commercial expansion, BD and pipeline programs without near-term refinancing risk. This supports execution on multi-year growth plans and cushions legal or market-access shocks that could otherwise strain operations.
High Margins & Cash ConvertibilityConsistently strong gross margins and operating cash flow that materially exceed reported net income indicate durable earnings quality. The near 1:1 free cash flow conversion reinforces sustainable cash generation to support reinvestment, dividends or acquisitions even if top-line growth moderates.
Commercial Momentum / Patient TractionRecord quarterly WAKIX revenue and management reaffirmation show effective commercial execution and growing prescription adoption. With current estimated market penetration near ~10%, sustained uptake implies a sizable addressable patient runway and durable revenue base for years ahead.
Bears Say
Rising Cost Of Goods SoldAn increase in COGS driven by new royalties from licensing compresses gross margins and reduces incremental cash generated per unit sold. If these royalty obligations persist or increase, they will structurally lower profitability and free cash flow margins unless offset by higher pricing or mix improvements.
Elevated Operating ExpensesA material rise in operating costs, including a sizable upfront license fee, depresses near-term GAAP earnings and cash flow. Continued higher R&D, BD and commercial spend to support pipeline and launches will keep operating leverage muted until new assets materially contribute revenues.
Multi-year Legal & Competitive RiskProtracted litigation timelines and appeals introduce uncertainty around exclusivity and potential generic entry, which could materially erode revenues. Separately, advancing orexin agonist competitors raise structural risk that future launches may face tougher pricing and market share dynamics when new products reach market.
Harmony Biosciences Holdings News
HRMY FAQ
What was Harmony Biosciences Holdings, Inc.’s price range in the past 12 months?
Harmony Biosciences Holdings, Inc. lowest stock price was $25.52 and its highest was $40.87 in the past 12 months.
What is Harmony Biosciences Holdings, Inc.’s market cap?
Harmony Biosciences Holdings, Inc.’s market cap is $2.13B.
When is Harmony Biosciences Holdings, Inc.’s upcoming earnings report date?
Harmony Biosciences Holdings, Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 12 days.
How were Harmony Biosciences Holdings, Inc.’s earnings last quarter?
Harmony Biosciences Holdings, Inc. released its earnings results on May 07, 2026. The company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.695 by -$0.145.
Is Harmony Biosciences Holdings, Inc. overvalued?
According to Wall Street analysts Harmony Biosciences Holdings, Inc.’s price is currently Undervalued.
Does Harmony Biosciences Holdings, Inc. pay dividends?
Harmony Biosciences Holdings, Inc. does not currently pay dividends.
What is Harmony Biosciences Holdings, Inc.’s EPS estimate?
Harmony Biosciences Holdings, Inc.’s EPS estimate is 0.92.
How many shares outstanding does Harmony Biosciences Holdings, Inc. have?
Harmony Biosciences Holdings, Inc. has 57,892,677 shares outstanding.
What happened to Harmony Biosciences Holdings, Inc.’s price movement after its last earnings report?
Harmony Biosciences Holdings, Inc. reported an EPS of $0.55 in its last earnings report, missing expectations of $0.695. Following the earnings report the stock price went down -4.149%.
Which hedge fund is a major shareholder of Harmony Biosciences Holdings, Inc.?
Currently, no hedge funds are holding shares in HRMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Harmony Biosciences Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.00 (40.05% Upside)
$42.00 (40.05% Upside)
Blogger Sentiment
Bullish
HRMY Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 142.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 8.4%
Last 30 Days ▲ 8.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
20.49%
Trailing 12-Months
Company Description
Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
HRMY Stock 12 Month Forecast
Average Price Target
$42.00
▲(40.05% Upside)
Technical Analysis
Ownership Overview
1.11% Insiders
20.89% Mutual Funds
0.54% Other Institutional Investors
47.17% Public Companies and
Individual Investors